Symbols

EQ

Equillium·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Strong Buy"

Bearish Engulfing

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EQ

Equillium, Inc.

A clinical-stage biotechnology company that developing novel therapeutics for severe autoimmune and inflammatory disorders

Industry

Pharmaceutical

Established Date

03/16/2017

Listing Date

10/12/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.equilliumbio.com

Security Type

Common stock

Office address

2223 Avenida de la Playa Suite 105 La Jolla CA 92037

Business

Introduction

Equillium, Inc., formerly Attenuate Biopharmaceuticals, Inc., was incorporated in Delaware on March 16, 2017. The company is a biotechnology innovator dedicated to developing novel therapies for the treatment of severe autoimmune and inflammatory diseases. Its lead drug candidate, EQ504, is a preclinical stage AhR modulator that initially targets ulcerative colitis, in addition to an oral bispecific inhibitor program in the preclinical stage for gastrointestinal indications.

Company Financials

EPS

EQ has released its 2025 Q4 earnings. EPS was reported at -0.04, versus the expected -0.07, beating expectations. The chart below visualizes how EQ has performed over recent quarters, highlighting trends in earnings surprises.